Human CD326 (EpCAM, EGP2, HEA) is a 40kD glycoprotein expressed on epithelial cells and many carcinomas.  It is an adhesion molecule whose function is implicated in carcinogenesis and erythropoesis. CD326 has great potential as a therapeutic and diagnostic marker for cancer (2, 3). 1) Rao CG, et al. (2005) Int. J. Oncol  27: 49 2) […]

Using transgenic mouse models and BM transplantation, it was observed that numbers of expanded thymic Treg are proportionate to number of thymic B cells present during autoimmune development. “A Role for Intrathymic B Cells in the Generation of Natural Regulatory T Cells.” Stacey N Walters, Shane Grey, et al. (2014) J Immunol 193(1): 170-176. PMID:24872190

CD273 binds to a distinct site on RGMb (Repulsive Guidance Molecule Family member B) from Bone Morphogenic proteins (BMP).  In mice, blockade of this interaction impaired development of respiratory tolerance. “RGMb is a novel binding partner for PD-L2 and its engagement with PD-L2 promotes respiratory tolerance”  Y Xiao, G J Freeman, et al. (2014) JEM

  anti-GARP/FITC  catalog #277-040 anti-GARP/PE  catalog #277-050 anti-GARP/Biotin  catalog #277-030 anti-GARP mAb catalog #277-020   Other Ancell human Treg Products   CD4 CD39 CD357(AITR/GITR) CD45RA CD45RO CD127 CD25

This German research group has developed a method to directly culture Pre and Pro B cells from CD34+ sorted Bone Marrow using cytokines and immobilized recombinant CD54. “A Feeder-Free Differentiation System Identifes Autonomously Proliferating B Cell precursors in Human Bone Marrow”  H Kraus, M Rizzi, et al. (2014)  J Immunol 192(3): 1044-1054. PMID: 24379121  

“GARP  regulates the bioavailability and activation of TGFbeta”  R Wang, T A Springer, et al. (2012) Mol Biol Cell 23(6): 1129-1139. Look for new Ancell anti-GARP products March 2014! Ancell human Treg Products CD4 CD39 CD357(AITR/GITR) CD45RA CD45RO CD127 CD25

Visit Ancell at the 56th ASH Annual Meeting and Exposition in New Orleans Dec 7 – 9  Booth # 2671!

Agonistic humanized anti-CD134(OX40) antibodies improve T effector cell function by depleting T regulatory cells in vitro.  This approach has great potential for augmenting cancer therapy! “Antibodies Targeting Human OX40 Expand Effector T Cells and Block Inducible and Natural Regulatory T Cell Function” K.S. Voo, Y.J. Liu, et al. (2013) J Immunol 191: 3641-3650. PMID: 24014877

New Ancell Products for human Dendritic cell research! Recombinant human CD279(PD-1) (CHO cell host) Recombinant human CD273(B7-DC) (CHO cell host) anti-human CD279(PD-1) antibody (clone ANC4H6) anti-human CD273(B7-DC) antibody (clone ANC8D12)   Other related products anti-human CD274(B7-H1) antibody Recombinant human CD274(B7-H1) (CHO cell host) anti-CD11b antibody (clone ICRF44) anti-CD14 antibody (clone UCHM1)

The BTLA(CD272)-HVEM(CD270) pathway is an important regulatory mechanism for gamma/delta T cell proliferation. A subset of gamma/delta T cells can be induced to have potent anti-Lymphoma activity.  The amount of BTLA present on cell surface of these cells inversely correlates with their degree of differentiation. Blockade of this pathway can increases T cell signaling ability,